倍他乐克治疗充血性心力衰竭临床观察

Efficaey and toxicity and analysis of Betaloc in the treatment of chronie congestive heart failure

目的观察倍他乐可治疗心力衰竭的心功能影响及疗效。方法120例患者随机分成治疗组和对照组各60例,均予心力衰竭常规治疗。治疗组加用倍他乐克。于治疗前后测定两组左心室收缩末期容积和左心室舒张末期容积,并进行临床疗效评价。结果两组治疗后LVESV较治疗前均明显改善,P<0.01;治疗后治疗组LVESV改善明显优于对照组,P<0.01,治疗组临床总有效率为83.4%,明显高于对照组63.3%,P<0.05。结论倍他乐克能明显改善CHF患者的临床症状和心功能。

Objective To observe the cardiac function and safety of betaloc in the treatment of chronic congestive heart failure（CHF）. Methods A total of 120 CHF patients were randomly divided into the control and treatment group. Each consisted of 60 case. The former received conventional therapy of heart failue for 12 weeks. While treatment group received conventional therapy and belaloc. The left ventricular end-systolic vol- ume（LVESV） and left ventricular end diastolic volume（LVEDV） were measured before and after treatment in both two groups, and the effectiveness was assessed. Result The LVESV was significantly improved after ther- apy in both two groups as compared with that before treatment, both P 〈 0. 01 （ t = 48. 810, 3. 846） ; The post- treatment LVESV improvement in the treatment group was markedly superior to that of the control group, P 〈 0.01 （ t = 2. 833 ）. The total clinical effective rate of the treatment group was 83.4%. Which was superior to 63.3 % of the control group, P 〈 0. 05 （χ^2 = 61.48）. Conclusion Belaloc can considerably improve the clinical symptoms and cardiac function if CHF pations.